Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.73 |
| ▸ | SPR | P35270 | 3/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23630270 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL23630280 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL3815737 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL23630267 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL23630266 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL23643317 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL23630276 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL23630268 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL1746356 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR | |
| SCHEMBL1746699 | 1.00 | TRPV1 (1.00) | TRPV1FAAHPTGS2MTNR1ASPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896600-B2 | Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders | Vidya Herbs, Inc. (US) | 2024-02-13 | — | — | US | claimed |
| US-20210369720-A1 | SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-12-02 | — | — | US | claimed |
| EP-3207029-B1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | SIGNUM BIOSCIENCES INC (US) | 2021-08-04 | — | — | EP | claimed |
| CN-107108495-B | Chromate compositions and methods of use | 希格诺生物科学有限公司 | 2021-07-16 | — | — | CN | claimed |
| WO-2021141439-A1 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE CONTAINING COFFEE SILVER SKIN EXTRACT, FRACTION THEREOF, OR COMPOUND ISOLATED THEREFROM | 강릉원주대학교산학협력단 | 2021-07-15 | — | — | WO | claimed |
| US-20210085690-A1 | COMPOSITION AND METHOD OF USING EICOSANOYL-5-HYDROXYTRYPTAMIDE FOR TREATING NEURODEGENERATIVE DISORDERS | Prasad Kodimule Shyam (IN) | 2021-03-25 | — | — | US | claimed |
| US-10314817-B2 | Tryptamide compositions and methods of use | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | claimed |
| EP-3207029-A1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | Signum Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | claimed |
| US-20170231955-A1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | SIGNUM BIOSCIENCES, INC. | 2017-08-17 | — | — | US | claimed |
| WO-2016061357-A1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | SIGNUM BIOSCIENCES, INC. (US) | 2016-04-21 | — | — | WO | claimed |
| US-11896600-B2 | Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders | Vidya Herbs, Inc. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11896600-B2 | Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders | Vidya Herbs, Inc. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230054976-A1 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | UNIVERSITY OF FLORIDA BOARD OF TRUSTEES | 2023-02-23 | — | — | US | disclosed |
| WO-2021127367-A9 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20210369720-A1 | SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-12-02 | — | — | US | disclosed |
| WO-2016061357-A1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | SIGNUM BIOSCIENCES, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016061357-A1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | SIGNUM BIOSCIENCES, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| EP-2282735-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | Signum Biosciences, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009132051-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | TRPV1 4687/4885FAAH 4119/4885PTGS2 2722/4885 |
| US-10314817-B2 | Tryptamide compositions and methods of use | HNMT, TPH2, TPH1 | TRPV1 880/4885FAAH 37/4885PTGS2 738/4885 |
| US-20170231955-A1 | TRYPTAMIDE COMPOSITIONS AND METHODS OF USE | HNMT, TPH2, TPH1 | TRPV1 880/4885FAAH 37/4885PTGS2 738/4885 |
| US-20210369720-A1 | SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF | BDNF, TPH2, TPH1 | TRPV1 1255/4885FAAH 20/4885PTGS2 1405/4885 |
| US-20230054976-A1 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | SNCA, EIF2AK2, LRRK2 | TRPV1 3449/4885FAAH 4218/4885PTGS2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.